142 related articles for article (PubMed ID: 8695248)
41. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.
J Clin Oncol; 1997 Jan; 15(1):124-30. PubMed ID: 8996133
[TBL] [Abstract][Full Text] [Related]
42. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
[TBL] [Abstract][Full Text] [Related]
43. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Forni C; Ferrari S; Loro L; Mazzei T; Beghelli C; Biolchini A; Simoni P; Tremosini M; Strazzari S; Puggioli C; Bacci G
Support Care Cancer; 2000 Mar; 8(2):131-3. PubMed ID: 10739360
[TBL] [Abstract][Full Text] [Related]
44. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
45. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: a randomized crossover study.
Poon RT; Chow LW
Br J Cancer; 1998 May; 77(10):1683-5. PubMed ID: 9635849
[TBL] [Abstract][Full Text] [Related]
46. Ondansetron suppository: an effective treatment for the prevention of emetic disorders induced by cisplatin-based chemotherapy. French Ondansetron Study Group.
Fumoleau P; Giovannini M; Rolland F; Votan B; Paillarse JM
Oral Oncol; 1997 Sep; 33(5):354-8. PubMed ID: 9415336
[TBL] [Abstract][Full Text] [Related]
47. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
48. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting.
Fedele P; Spina M; Valentini M; Collini D; Lucia C; Manicone M; Tirelli U
Cancer; 1995 Aug; 76(3):535-6. PubMed ID: 8625142
[No Abstract] [Full Text] [Related]
49. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
[TBL] [Abstract][Full Text] [Related]
50. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.
de Wit R; van den Berg H; Burghouts J; Nortier J; Slee P; Rodenburg C; Keizer J; Fonteyn M; Verweij J; Wils J
Br J Cancer; 1998 May; 77(9):1487-91. PubMed ID: 9652766
[TBL] [Abstract][Full Text] [Related]
51. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.
Navari RM; Madajewicz S; Anderson N; Tchekmedyian NS; Whaley W; Garewal H; Beck TM; Chang AY; Greenberg B; Caldwell KC
J Clin Oncol; 1995 Sep; 13(9):2408-16. PubMed ID: 7666101
[TBL] [Abstract][Full Text] [Related]
52. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. A cost-benefit analysis.
Barrajon E; de las Peñas R
Support Care Cancer; 2000 Jul; 8(4):323-33. PubMed ID: 10923774
[TBL] [Abstract][Full Text] [Related]
53. Antiemetic prophylaxis with ondansetron and methylprednisolone vs metoclopramide and methylprednisolone in mild and moderately emetogenic chemotherapy.
Tsavaris NB; Koufos C; Katsikas M; Dimitrakopoulos A; Athanasiou E; Linardaki G
J Pain Symptom Manage; 1999 Sep; 18(3):218-22. PubMed ID: 10517044
[TBL] [Abstract][Full Text] [Related]
54. Methylprednisolone enhances the efficacy of ondansetron in acute and delayed cisplatin-induced emesis over at least three cycles. Ondansetron Study Group.
Chevallier B; Marty M; Paillarse JM
Br J Cancer; 1994 Dec; 70(6):1171-5. PubMed ID: 7981071
[TBL] [Abstract][Full Text] [Related]
55. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
[TBL] [Abstract][Full Text] [Related]
56. [Value of the combination of oral ondansetron with methylprednisolone as soon as the first cure in mild emetogenic chemotherapy. Groupe français d'étude de l'ondansétron].
Coiffier B; Khayat D; Misset JL; Votan B
Bull Cancer; 1997 Aug; 84(8):781-7. PubMed ID: 9339181
[TBL] [Abstract][Full Text] [Related]
57. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
58. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
59. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. Ondansetron Study Group.
Seynaeve C; Schuller J; Buser K; Porteder H; Van Belle S; Sevelda P; Christmann D; Schmidt M; Kitchener H; Paes D
Br J Cancer; 1992 Jul; 66(1):192-7. PubMed ID: 1386245
[TBL] [Abstract][Full Text] [Related]
60. Comparison of granisetron alone and granisetron plus hydroxyzine hydrochloride for prophylactic treatment of emesis induced by cisplatin chemotherapy.
Tsukuda M; Furukawa S; Kokatsu T; Enomoto H; Kubota A; Furukawa M
Eur J Cancer; 1995 Sep; 31A(10):1647-9. PubMed ID: 7488417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
